Age: 56 Gender: Female Patient: 1017-010 Study: Pivotal Study
Baseline
Week 4
Week 12
Age: 67 Gender: Male Patient: 2030-001 Study: Pivotal Study
Baseline
Week 4
Week 12
Age: 63 Gender: Male Patient: 2014-011 Study: Pivotal Study
Baseline
Week 4
Week 12
Age: 66 Gender: Male Patient: 1006-001 Study: Phase 4, open-label Intertriginous Plaque Psoriasis (in the skin folds) study
Baseline
Week 1
Week 12
Baseline
Week 4
Week 12
Age: 24 Gender: Male Patient: 1006-02 Study: Phase 4, open-label, Head and Neck Plaque Psoriasis study
Baseline
Week 4
Week 12
Age: 75 Gender: Female Patient: 1007-02 Study: Phase 4, open-label, Head and Neck Plaque Psoriasis study
Baseline
Week 1
Week 12
Age: 55 Gender: Female Patient: 1003-01 Study: Phase 4, open-label, Head and Neck Plaque Psoriasis study
Baseline
Week 1
Week 12
Age: 56 Gender: Female Patient: 1017-010 Study: Pivotal Study
Baseline
Week 4
Week 12
Age: 67 Gender: Male Patient: 2030-001
Baseline
Week 4
Week 12
Age: 63 Gender: Male Patient: 2014-011
Baseline
Week 4
Week 12
Take a look at the results! These images show the progress of some patients after using VTAMA cream for 12 weeks.
Take a look at what adult patients with plaque psoriasis experienced in clinical trials.
Up to 48% of adult patients achieved at least 75% clearer skin in 12 weeks while using VTAMA cream (compared to 10% using a cream with no active ingredient).
Up to 80% of adult patients saw some level of improvement* in their plaques within 12 weeks while using VTAMA cream (compared to 35% using a cream with no active ingredient).
Of adult patients with mild-to-severe plaque psoriasis, 58% achieved clear or almost clear skin at least once in the 40-week, open-label, long-term extension study.
VTAMA cream was proven to be safe and well tolerated for long-term use, as demonstrated in 52-week clinical trials.
The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).
Ask your healthcare provider if VTAMA cream is right for you.
*Physician Global Assessment (PGA) score of ≥1-grade improvement from baseline at Week 12.
Patients who achieved clear skin while on VTAMA cream were able to stop treatment and maintained clearer skin for an average of ~4 months!
In an open-label, long-term clinical study, 312 patients achieved clear skin at least once during the study and stopped using VTAMA cream. The average time before their skin was no longer clear (or almost clear†) and patients had to start using VTAMA cream again was ~4 months.
Psoriasis plaques were measured using the Physician Global Assessment (PGA), a scoring system used by healthcare providers, where clear skin was defined as a PGA score of 0 and almost clear skin was defined as a PGA score of 1.
Plaque psoriasis is complicated, but we’re here to break it down. Here's how tapinarof (the active ingredient in VTAMA cream) supports healthy skin function in adults:
There are receptors in your skin called Aryl hydrocarbon Receptors (AhR for short), and they play an important role in regulating your skin. But your skin's natural balance is disrupted when you have plaque psoriasis. Tapinarof helps fix the imbalance by supporting AhR. The specific way in which VTAMA cream works in psoriasis is unknown.
Tapinarof reduces the activity of cells in the skin that causes inflammation, as seen in studies of mice and skin outside of the body.
Tapinarof acts as a modulator of skin barrier proteins and works to keep them at normal levels, as seen in studies of skin outside of the body.
Skin barrier proteins are essential proteins for the correct formation and function of the skin barrier. They’re very important to the function of healthy skin, but are found to be reduced in plaque psoriasis.
Tapinarof increases your antioxidant activity, which decreases oxidative stress in your skin, as demonstrated in skin studies outside of the body.
Sign up today to get the latest around plaque psoriasis, VTAMA (tapinarof) cream, 1%, and other helpful tips and information.
*Required field
When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.
 Strictly Necessary Cookies
|
Always active |
|
Performance Cookies
|
|
|
Targeting Cookies
|
Make sure to sign up for more education on plaque psoriasis and VTAMA cream before you leave the site.
Thank you for signing up. You’ll be hearing from us soon.
Have more questions? Chat live with a nurse.
No thanks, take me to the VTAMA cream website
for adults with plaque psoriasis
No thanks, take me to the VTAMA
cream website for adults with plaque psoriasis
IMPORTANT SAFETY INFORMATION
Indications: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for:
Adverse Events: In plaque psoriasis, the most common adverse reactions (incidence ≥1%) were: red raised bumps around the hair pores (folliculitis), pain or swelling in the nose and throat (nasopharyngitis), skin rash or irritation, including itching and redness, peeling, burning, or stinging (contact dermatitis), headache, itching (pruritus), and flu (influenza).
Adverse Events: In atopic dermatitis, the most common adverse reactions (incidence ≥1%) were: upper respiratory tract infection, red raised bumps around the hair pores (folliculitis), lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and stomach-area (abdominal) pain.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
